Wedbush Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN)

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Stock analysts at Wedbush raised their Q1 2025 EPS estimates for Arvinas in a research report issued on Tuesday, February 11th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.93) for the quarter, up from their previous estimate of ($1.57). Wedbush currently has a "Outperform" rating and a $57.00 price target on the stock. The consensus estimate for Arvinas' current full-year earnings is ($3.22) per share. Wedbush also issued estimates for Arvinas' Q2 2025 earnings at ($0.94) EPS, Q3 2025 earnings at ($0.95) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.75) EPS, FY2026 earnings at ($3.17) EPS, FY2027 earnings at ($3.30) EPS and FY2028 earnings at ($3.51) EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period last year, the company posted ($2.53) EPS.

Several other brokerages also recently issued reports on ARVN. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. BTIG Research initiated coverage on Arvinas in a report on Tuesday, December 10th. They set a "buy" rating and a $69.00 target price for the company. Barclays dropped their target price on Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. HC Wainwright reissued a "buy" rating and set a $87.00 target price on shares of Arvinas in a report on Wednesday, December 11th. Finally, Guggenheim reissued a "buy" rating and set a $57.00 target price on shares of Arvinas in a report on Wednesday, February 12th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, Arvinas currently has a consensus rating of "Buy" and a consensus price target of $60.00.

Arvinas Price Performance

Arvinas stock traded up $0.32 during mid-day trading on Friday, hitting $18.63. 1,789,729 shares of the company's stock traded hands, compared to its average volume of 942,180. The firm has a 50 day simple moving average of $18.63 and a two-hundred day simple moving average of $23.05. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $51.99. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -3.99 and a beta of 1.88.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC acquired a new position in Arvinas in the third quarter valued at about $39,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock valued at $61,000 after purchasing an additional 440 shares in the last quarter. KBC Group NV raised its stake in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock valued at $55,000 after purchasing an additional 1,255 shares in the last quarter. Quantbot Technologies LP grew its position in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock valued at $108,000 after acquiring an additional 2,601 shares during the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Arvinas by 37.0% in the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock valued at $164,000 after acquiring an additional 1,798 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company's stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.